MedTrace Logo

PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer

NCT03166085 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2021-12-20

No results posted yet for this study

Summary

The purpose of this study is to decide the best dose of the study drug, PU-H71, that can be given in combination with the standard chemotherapy drug, nab-paclitaxel (Abraxane).

Conditions

Interventions

DRUG

PU-H71

PU-H71 will be given as an intravenous infusion on Day 1 of a 21 day cycle

DRUG

Nab-paclitaxel

nab-paclitaxel will be administered at a dose of 260mg/m2 intravenously on Day 1

Sponsors & Collaborators

Principal Investigators

  • Shanu Modi, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-23
Primary Completion
2021-12-14
Completion
2021-12-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03166085 on ClinicalTrials.gov